There were some beneficial effects compared to placebo or antidepressants but tolerability was worse .
Quetiapine was more effective than placebo treatment .
Aripiprazole and quetiapine and partly also olanzapine and risperidone augmentation showed beneficial effects compared to placebo .
Some evidence indicated beneficial effects of low-dose amisulpride for dysthymic people .
Most SGAs showed worse tolerability
BACKGROUND Major depressive disorder ( MDD ) is a common condition with a lifetime prevalence of 15 % to 18 % , which leads to considerable suffering and disability .
Some antipsychotics have been reported to induce remission in major depression , when added to an antidepressant .
OBJECTIVES To evaluate the effects of second-generation antipsychotic ( SGA ) drugs ( alone or augmentation ) compared with placebo or antidepressants for people with MDD or dysthymia .
A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs. amisulpride in the treatment of dysthymia
AIM Evaluation of the effect of acetyl-L-carnitine ( ALCAR ) vs. amisulpride measured by total Hamilton Depression Rating Scale score ( HAM-D(21 ) ) in patients with pure dysthymia ( DSM IV ) . Two hundred and four patients were r and omised and treated with ALCAR 500 mg b.i.d . or amisulpride 50 mg u.i.d . in a double-blind study , for 12 weeks . RESULTS A solid improvement of HAM-D(21 ) was observed in both treatment groups throughout the study . The results did not disclose statistically significant differences between treatments , although the confidence interval for the non-inferiority of the primary end-point exceeded the pre-established limit of 2 by 0.46 points . According to a non-inferiority margin of 3 ( considered acceptable by recent published data ) the primary end-point could have been fully satisfied . CDRS , MADRS and CGI , employed to further measure the clinical outcome , reported similar results in both treatment groups . The greater tolerability of ALCAR is of clinical relevance considering the chronicity of  dysthymia  , which often requires prolonged treatment
There were some beneficial effects compared to placebo or antidepressants but tolerability was worse .
Quetiapine was more effective than placebo treatment .
Aripiprazole and quetiapine and partly also olanzapine and risperidone augmentation showed beneficial effects compared to placebo .
Some evidence indicated beneficial effects of low-dose amisulpride for dysthymic people .
Most SGAs showed worse tolerability
BACKGROUND Major depressive disorder ( MDD ) is a common condition with a lifetime prevalence of 15 % to 18 % , which leads to considerable suffering and disability .
Some antipsychotics have been reported to induce remission in major depression , when added to an antidepressant .
OBJECTIVES To evaluate the effects of second-generation antipsychotic ( SGA ) drugs ( alone or augmentation ) compared with placebo or antidepressants for people with MDD or dysthymia .